Breast and Endocrine Surgery
A 38-year-old Emirati teacher attends your clinic with a firm 2.5 cm lump in the upper outer quadrant of the right breast that she has noticed for three months. Her mother had breast cancer at 44 and a maternal aunt had ovarian cancer at 51. She is married with two young children and asks whether she should just have both breasts removed to be safe. Ultrasound shows an irregular hypoechoic mass with an indeterminate axillary node. How do you proceed?
What the panel is testing: The panel is testing structured triple assessment, understanding of hereditary risk and genetic referral, and the ability to counsel a frightened young woman on surgical options without steering her.
Show the answer outline
Knowledge: Any discrete lump in a woman of this age requires formal triple assessment, and I would not discuss any surgical option until I have a tissue diagnosis. Clinically and sonographically this is suspicious, and the family history of early breast cancer plus ovarian cancer in a second-degree relative on the same side raises the possibility of a BRCA1 or BRCA2 pathogenic variant, which would change surgical decision making, systemic therapy options and family screening.
Management: I would perform bilateral mammography with tomosynthesis and targeted ultrasound of the breast and axilla, and take an ultrasound-guided core biopsy of the mass plus a fine needle aspirate or core of the indeterminate node, with clip placement in the tumour and in the node if it is positive.
Ethics and communication: Her request for bilateral mastectomy is driven by fear, and my professional duty is neither to dismiss it nor to accede to it, but to slow the process down, name the fear, and provide the information she needs to make an autonomous decision once the diagnosis and genetic status are known.
Likely panel follow-up questions
- What are the components of triple assessment and how do you grade each one?
- How would a BRCA1 pathogenic variant change your surgical and systemic plan?
- When would you recommend neoadjuvant systemic therapy rather than upfront surgery?
Pitfalls in this case
- Agreeing to bilateral mastectomy before a tissue diagnosis and genetic result
- Omitting axillary node assessment at the time of the initial ultrasound
- Failing to refer for genetics or to raise fertility preservation
Reference: NICE Guideline NG101, Early and Locally Advanced Breast Cancer: Diagnosis and Management, 2018 updated 2023; NCCN Clinical Practice Guidelines in Oncology, Breast Cancer and Genetic/Familial High-Risk Assessment, 2024